announced a $20 million credit investment from Catalio Capital Management, a leading investment firm dedicated to backing innovative healthcare companies. The funding will accelerate the scaling of Amalgam’s Medical-Grade AI solutions to further empower patients in their daily lives and providers in their clinical workflows.

The senior secured term loan provides Amalgam with an initial draw of $12 million at close to continue its market expansion and refinance existing corporate debt. Amalgam will also gain access to Catalio’s extensive network of life sciences leaders, including its board of advisors and 45+ Catalio Venture Partners – comprised of world-renowned, serial scientist-entrepreneurs with a proven track record in starting category-defining businesses – who will provide strategic insights to support product development and commercial growth.

“Our investment in Amalgam reflects Catalio’s commitment to backing the next generation of pioneering healthcare companies. Amalgam’s proven track record, scalable platform, and vision for intelligent, personalized care position them as a leader in facilitating high quality care. We’re proud to support the company’s next phase of growth as they continue to drive innovation at the intersection of digital health and life sciences,” said Catalio’s Dr. Nicholas von Guionneau, who joins Amalgam’s Board of Directors as an Observer.

“We’re excited to welcome Catalio as a strategic partner through its $20 million credit investment. Catalio’s deep expertise in healthcare and life sciences, combined with their expansive venture network, makes them an ideal partner as we scale. This funding will accelerate the development and deployment of our medical-grade AI platform – enhancing decision-making for both patients and providers – and advance our mission to transform chronic disease management through intelligent, personalized care,” said Ryan Sysko, Chief Executive Officer of Amalgam Rx.

As healthcare increasingly adopts AI, ensuring safety, compliance, and integrity is paramount. Amalgam has spent five years developing its proprietary Medical-Grade AI, a platform engineered with built-in safeguards to meet rigorous clinical, ethical, and regulatory standards. This enables healthcare organizations to safely, quickly, and confidently harness the power of AI.

Amalgam’s financial advisor was KOI Capital Group and was represented by Nemphos Braue LLC. Catalio was represented by Covington & Burling LLP.